Home » Stealth BioTherapeutics Inc.

Tag: Stealth BioTherapeutics Inc.

Post
Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories

Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories

Pharmanovia Obtains Exclusive License to Commercialize Elamipretide for the Treatment of Barth Syndrome in the European Union, United Kingdom, Middle East, and Northern Africa NEEDHAM, Mass., May 30, 2023 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth BioTherapeutics”), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases...